Last Updated on November 11, 2024 by The Health Master
The United States Food and Drug Administration (USFDA) has approved a Formulation manufacturing facility of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma.
The USFDA inspected Unit I, a Formulation manufacturing facility of Eugia Pharma Specialities situated at Koltur Village, Shameerpet, Medchal District, Telangana, from July 17-26, 2023.
“The inspection closed with zero observations and a classification of No Action Indicated (NAI),” Hyderabad-based Aurobindo said in a release.
USFDA issues Form 483 with 3 observations to Aurobindo: Hyderabad
USFDA issues Form 483 with 8 observations to Biocon: Malaysia
USFDA issues Form 483 with one observation to Gland Pharma: Hyderabad
USFDA issues Form 483 to Lupin with 2 observations: Nagpur
USFDA completes inspection of Granules India in two facilities
USFDA completes inspection at Ajanta Pharma with zero observations: Gujarat
The need for uniform pricing of Medical Devices and Surgical Products
USFDA gives approval for Plerixafor injectionTypes of inspections done by USFDA: Read in detail
Title: CDSCO asks to submit online applications for Veterinary Vaccine and drug test
An overview of Legislative Bills related to Pharma in the ongoing Parliament Session
Drug alert: 48 out of 1273 samples declared as NSQ in June 2023
Indian Pharma Industry wants to end multiple inspections by USFDA
Govt asks Medical Stores not to sell painkillers without prescription: Delhi
AHUs, Air Types, Air Changes and their Functions in Pharma Industry
Pharmacy Council appoints four Pharmacy Inspectors: Karnataka
